The Company accounts for share-based compensation under the provisions of ASC 718, Compensation - Stock Compensation, which requires the Company to measure and recognize compensation expense for all share-based payments at fair value.

Total share-based compensation expense included in the Consolidated Statements of Operations for the 13 and 39 weeks ended October 29, 2022 was $6.8 million ($4.9 million, net of tax) and $30.0 million ($19.7 million, net of tax), respectively, and for the 13 and 39 weeks ended October 30, 2021 was $7.9 million ($5.9 million, net of tax) and $29.4 million ($22.2 million, net of tax), respectively.

The Company has granted time-based stock option awards, which vest over the requisite service period of the award or at an employee’s eligible retirement date, if earlier. A summary of the Company’s stock option activity for the 39 weeks ended October 29, 2022 follows:


				Weighted- Average		Weighted- Average Remaining Contractual		Aggregate
	Options			Exercise Price		Term		Intrinsic Value
	(In thousands)					(In years)		(In thousands)
Outstanding - January 29, 2022		3,647		$	16.74
Granted		1,094		$	17.24
Exercised		(108	)	$	8.62
Cancelled		(617	)	$	16.87
Outstanding - October 29, 2022		4,016		$	17.07		4.1		1,708
Vested and expected to vest - October 29, 2022		2,856		$	17.01		2.9		550
Exercisable - October 29, 2022 (1)		433		$	9.91		4.4		1,139

(1)

Options exercisable represent “in-the-money” vested options based upon the weighted-average exercise price of vested options compared to the Company’s stock price on October 29, 2022.

Cash received from the exercise of stock options and the actual tax benefit realized from share-based payments was $1.8 million and $0.3 million, respectively, for the 39 weeks ended October 29, 2022. Cash received from the exercise of stock options and the actual tax benefit realized from share-based payments was $13.1 million and $4.3 million, respectively, for the 39 weeks ended October 30, 2021.

As of October 29, 2022, there was $7.6 million of unrecognized compensation expense for stock option awards that is expected to be recognized over a weighted average period of 2.0 years.

The fair value of stock options was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:


	39 Weeks Ended			39 Weeks Ended
	October 29,			October 30,
Black-Scholes Option Valuation Assumptions	2022			2021
Risk-free interest rate (1)		2.5	%		0.9	%
Dividend yield		3.8	%		1.6	%
Volatility factor (2)		52.2	%		50.7	%
Weighted-average expected term (3)	4.5 years			4.5 years

(1)

Based on the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected life of our stock options.

(2)

Based on historical volatility of the Company’s common stock.

Time-based restricted stock awards are comprised of time-based restricted stock units. These awards vest over three years. Time-based restricted stock units receive dividend equivalents in the form of additional time-based restricted stock units, which are subject to the same restrictions and forfeiture provisions as the original award.

Performance-based restricted stock awards include performance-based restricted stock units. These awards cliff vest at the end of a three-year period based upon the Company’s achievement of pre-established goals throughout the term of the award. Performance-based restricted stock units receive dividend equivalents in the form of additional performance-based restricted stock units, which are subject to the same restrictions and forfeiture provisions as the original award.

The grant date fair value of time-based restricted stock awards is based on the closing market price of the Company’s common stock on the date of grant. A Monte-Carlo simulation was utilized for performance-based restricted stock awards.

A summary of the Company’s restricted stock activity is presented in the following table:


	Time-Based Restricted Stock Units					Performance-Based Restricted Stock Units
	October 29, 2022					October 29, 2022
(Shares in thousands)	Shares			Weighted- Average Grant Date Fair Value		Shares			Weighted- Average Grant Date Fair Value
Non-vested - January 29, 2022		2,702		$	16.25		1,462		$	20.95
Granted		1,598		$	16.51		549		$	19.16
Vested		(1,228	)	$	15.01		(257	)	$	21.28
Cancelled		(314	)	$	15.57		(180	)	$	22.39
Non-vested - October 29, 2022		2,758		$	17.03		1,574		$	20.11

As of October 29, 2022, there was $31.6 million of unrecognized compensation expense related to non-vested, time-based restricted stock unit awards that is expected to be recognized over a weighted-average period of 2.0 years. There was $8.3 million of unrecognized compensation expense related to performance-based restricted stock unit awards for which a Monte-Carlo simulation was performed that is expected to be recognized over a weighted period of 2.1 years.

As of October 29, 2022, the Company had 4.8 million shares available for all equity grants.